We found that high expression of TRAF1, CHST7 (excluded by qPCR data), PPL, and ERO1A (excluded by qPCR data and unexpected prognostic impact) was correlated with poor survival of MM patients in the Arkansas myeloma cohort [31], whereas the other potential targets of ALKBH5 did not show a prognostic significance in MM (Figs. 5H; S5C–L). Here, ALKBH5 is linked to plasma cell myeloma.